These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25672491)

  • 1. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.
    Rumpf T; Schiedel M; Karaman B; Roessler C; North BJ; Lehotzky A; Oláh J; Ladwein KI; Schmidtkunz K; Gajer M; Pannek M; Steegborn C; Sinclair DA; Gerhardt S; Ovádi J; Schutkowski M; Sippl W; Einsle O; Jung M
    Nat Commun; 2015 Feb; 6():6263. PubMed ID: 25672491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
    Schiedel M; Rumpf T; Karaman B; Lehotzky A; Oláh J; Gerhardt S; Ovádi J; Sippl W; Einsle O; Jung M
    J Med Chem; 2016 Feb; 59(4):1599-612. PubMed ID: 26696402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations.
    Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U
    Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Slow Off-Kinetics of Sirtuin-Rearranging Ligands (SirReals) by Means of Label-Free Electrically Switchable Nanolever Technology.
    Schiedel M; Daub H; Itzen A; Jung M
    Chembiochem; 2020 Apr; 21(8):1161-1166. PubMed ID: 31692222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Development of an Affinity Probe for Sirtuin 2.
    Schiedel M; Rumpf T; Karaman B; Lehotzky A; Gerhardt S; Ovádi J; Sippl W; Einsle O; Jung M
    Angew Chem Int Ed Engl; 2016 Feb; 55(6):2252-6. PubMed ID: 26748890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Continuous, Fluorogenic Sirtuin 2 Deacylase Assay: Substrate Screening and Inhibitor Evaluation.
    Galleano I; Schiedel M; Jung M; Madsen AS; Olsen CA
    J Med Chem; 2016 Feb; 59(3):1021-31. PubMed ID: 26788965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
    Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
    J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
    Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T
    J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opening the Selectivity Pocket in the Human Lysine Deacetylase Sirtuin2 - New Opportunities, New Questions.
    Robaa D; Monaldi D; Wössner N; Kudo N; Rumpf T; Schiedel M; Yoshida M; Jung M
    Chem Rec; 2018 Dec; 18(12):1701-1707. PubMed ID: 29931800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition.
    Kaya SG; Eren G; Massarotti A; Bakar-Ates F; Ozkan E; Gozelle M; Ozkan Y
    Drug Dev Res; 2024 Jun; 85(4):e22224. PubMed ID: 38867474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for potent inhibition of SIRT2 deacetylase by a macrocyclic peptide inducing dynamic structural change.
    Yamagata K; Goto Y; Nishimasu H; Morimoto J; Ishitani R; Dohmae N; Takeda N; Nagai R; Komuro I; Suga H; Nureki O
    Structure; 2014 Feb; 22(2):345-52. PubMed ID: 24389023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeding for sirtuins: microseed matrix seeding to obtain crystals of human Sirt3 and Sirt2 suitable for soaking.
    Rumpf T; Gerhardt S; Einsle O; Jung M
    Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1498-510. PubMed ID: 26625292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
    Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket.
    Sundriyal S; Moniot S; Mahmud Z; Yao S; Di Fruscia P; Reynolds CR; Dexter DT; Sternberg MJ; Lam EW; Steegborn C; Fuchter MJ
    J Med Chem; 2017 Mar; 60(5):1928-1945. PubMed ID: 28135086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
    Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M
    J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
    Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors.
    Scarano N; Abbotto E; Musumeci F; Salis A; Brullo C; Fossa P; Schenone S; Bruzzone S; Cichero E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
    Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*.
    Schiedel M; Lehotzky A; Szunyogh S; Oláh J; Hammelmann S; Wössner N; Robaa D; Einsle O; Sippl W; Ovádi J; Jung M
    Chembiochem; 2020 Dec; 21(23):3371-3376. PubMed ID: 32672888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
    Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
    Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.